๐ฐ Leukemia News
Page 85 - Leukemia News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.
December 11, 2023
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.
December 11, 2023
Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.
December 11, 2023
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
December 11, 2023
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
December 11, 2023
"Bring your mother so that we can do DNA first. Donโt try to put me in the media."
December 11, 2023
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens โ a major indicator of clinical improvement โ compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
December 11, 2023
The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.
December 10, 2023
Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.
December 10, 2023
Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.
December 10, 2023
New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.